CohBar Inc (NASDAQ: CWBR), in the latest announcement, provided an update on the phase 1a/1b clinical trial for CB4211 which is under development for NASH and obesity. In addition, the announcement was made to provide information on when data for its phase 1a/1b clinical study of CB4211 will be released. The study is initiated to find potential treatments for nonalcoholic steatohepatitis and obesity.
Topline data is expected to be released by the company before Labor Day 2021
If all works well, CohBar Inc will make data official before Labor Day 2021. Currently, the process of data entry and final validation by the company’s clinical research organization is ongoing. Before database lock, the research team must complete the process of data entry and validation. Only after the database is locked will external biostatisticians have access to the unblinded data from the study. After gaining access to the unblinded data, external biostatisticians will perform the data analysis and generate the final output. Once this process is completed, the team will hand over the data to the company.
CohBar Inc is a clinical-stage biotechnology company developing mitochondria-based therapeutics to treat chronic diseases and extend a healthy lifespan. The company has discovered more than 100 mitochondrial-derived peptides and generated over 1,000 analogs. It is learned that CohBar Inc has four preclinical programs, with the most advanced being CB5138-3 for idiopathic pulmonary fibrosis (IPF) and other fibrotic diseases, which is currently in IND-enabling studies.
Mitochondrial derived peptide (MDP) was discovered by CohBar Inc founder Dr. Pinchas Cohen and his team
CB4211 is a first-in-class mitochondria-based therapeutic (MBT) that has demonstrated significant therapeutic potential in preclinical models of nonalcoholic steatohepatitis (NASH) and obesity. Discovered by CohBar Inc founder Dr. Pinchas Cohen and his academic collaborators, MDP has played a significant role in regulating metabolism.
NASH is estimated to affect as many as 30 million adults in the U.S., and there is currently no approved treatment for the disease. Presently, the lead compound, CB4211, of CohBar Inc is in the Phase 1b stage of a Phase 1a/1b clinical trial for nonalcoholic steatohepatitis (NASH) and obesity.